A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma
Who is this study for? Adult patients with thymoma and thymic carcinomas
What treatments are being studied? Cisplatin+Etoposide+Radiotherapy
Status: Recruiting
Location: See location...
Intervention Type: Radiation, Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This study is designed to investigate whether adjuvant radiochemotherapy after incomplete resection has a better survival than adjuvant radiotherapy for thymoma or thymic carcinoma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• 18\
• 75 years old; Eastern Cooperative Oncology Group performance status of 0 to 2; Pathologically confirmed ; incomplete resection (R1 or R2);have adequate bone marrow, hepatic, and renal function;Patients receive incomplete resection within 3 months; Written informed consent.
Locations
Other Locations
China
Kailiang Wu
RECRUITING
Shanghai
Contact Information
Primary
Kailiang Wu, MD.PhD.
wukailiang@aliyun.com
+86 64175590
Backup
Xingwen Fan, MD
wenxingfan@126.com
+8613651669687
Time Frame
Start Date: 2023-12-01
Estimated Completion Date: 2026-12
Participants
Target number of participants: 1
Treatments
Experimental: Radiochemotherapy
adjuvant radiochemotherapy after incomplete resection: Cisplatin + Etoposide + Radiotherapy (60Gy / 30FX)
Sham_comparator: radiotherapy
adjuvant radiotherapy after incomplete resection: Radiotherapy (60Gy / 30FX)
Related Therapeutic Areas
Sponsors
Leads: Fudan University